51 results about "Cell Transdifferentiation" patented technology

Disclosed is an in vitro method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological features of a glial cell. Also disclosed are such transdifferentiated cells and cell cultures derived from them. A kit for converting, in vitro, epidermal basal cells into cells having one or more morphological, physiological and/or immunological features of a glial cell is also disclosed.

Disclosed is a method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and/or immunological features of a neural progenitor, neuronal, or glial cell by culturing a proliferating epidermal basal cell population derived from the skin of a mammalian subject; exposing the epidermal basal cell(s) to an antagonist of bone morphogenetic protein (BMP), such as fetuin, noggin, chordin, gremlin, or follistatin; and growing the cell(s) in the presence of at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and/or a segment of a human HES1 gene, or homologous non-human counterpart of either of these. Also disclosed is a transdifferentiated cell of epidermal origin and cell cultures derived therefrom. In addition, methods of using the inventive transdifferentiated cell(s) and cell cultures to identify a novel nerve growth factor or to screen a potential chemotherapeutic agent by detecting the presence or absence of an effect, in vitro, on a morphological, physiological and/or molecular biological property of the transdifferentiated cell(s) are described, as is a method of using the transdifferentiated cell(s) and cell cultures to screen a potential chemotherapeutic agent to treat a nervous system disorder of genetic origin. A kit useful for practicing the methods is disclosed

The subject invention comprises culture methods for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway. It also concerns the endocrine hormones that can be produced by such cultures, and the use of the transdifferentiated cells in the treatment of pancreatic diseases.

A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.

The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.

The invention discloses a small molecule compound combination and a method for preparing vascular endothelial cells by using the small molecule compound combination to induce differentiated cells. According to the method, differentiated cells are subjected to targeted induction so as to finally obtain vascular endothelial cells, wherein the targeted induction comprises: inhibiting the activity oflysine deacetylase activity, inhibiting the signaling pathway of TGF-beta, inhibiting the activity of DNA methyltransferase (DNMT), activating the signaling pathway of WNT/beta-catenin, and activatingthe signaling pathway of cAMP. According to the present invention, through the induction with the small molecule compound combination, the differentiated cells can be transdifferentiated into the vascular endothelial cells, each step can be subjected to precise quality control, and the standardized operation and the large-scale production can be conveniently achieved; and the donor source of themethod is wide, the patient himself can be served as the donor, and the vascular endothelial cells required by basic research, clinical treatment or tissue engineering production can be obtained within a short time.

Cosmetic formulations and compositions customized and/or personalized for rejuvenation of skin and/or hair are described. The cosmetic formulations are customized and/or personalized to include an extract and/or one or more molecular components in amounts and ratios naturally produced by rejuvenated cells or by cells modified toward rejuvenation. These cells are of skin and/or hair origin that have been reprogrammed, in which the skin and/or hair cells, having been rejuvenated and/or modified from the original cell, are initially obtained from a subject for which a customized cosmetic composition is for, or from a subject representative of a person for which a customized cosmetic composition is for. Reprogramming of the skin and/or hair cells provide rejuvenated cells, embryonic stem cell-like pluripotent cells, and/or transdifferentiated or differentiated young or younger cells that have been transdifferentiated from the rejuvenated or modified cells or differentiated from the embryonic stem cell-like pluripotent cells. Methods of selecting, preparing, and formulating the customized cosmetic products are also described.

The invention relates to the cell transdifferentiation technology in the field of cell research, in particular to a method for inducing neuroblastoma cells to be differentiated to nerve cells. The neuroblastoma cells are cultured for 3-7 days through an inducing culture medium, and then the nerve cells are obtained; the inducing culture medium is obtained by adding retinoic acid to a neural stem cell condition culture solution to 10 micrometers; a complete culture medium including a DMEM/F12 basic cukture mediam, B27, bFGF, EGF, heparn sodium, L-glutamine and mycillin is used for culturing the neural stem cells, the complete culture medium is replaced by a half after culturing is conducted for three days, and the replaced culture solution is the neural stem cell condition culture solution. By means of the method, the differentiation efficiency is improved, and the maturity of the cells and growth of neural synapses of nerve cells are also improved. The cell apoptosis in SH-SY5Y treated through RA can be inhibited.

The invention discloses a cell transdifferentiation method. The cell transdifferentiation method comprises the following steps that a lentiviral expression vector is adopted to prepare a lentivirus, the sequence of the lentiviral expression vector includes a transcription factor etv2; the lentivirus is adopted to infect a target cell line, culture is performed for 5-7 days, and then transdifferentiation of the target cell line is completed. The cell transdifferentiation method adopts the lentivirus as the carrier, the transcription factor etv2 is transfected to the target cell line, then culture is performed for 5-7 days to complete the transdifferentiation of the target cell line. FACS identification of the transdifferentiated target cell line shows that about 70% of cell expression endothelial cell molecular markers CD144 are found. It is found that genes relevant to blood vessels in transdifferentiated cells are improved at different degrees through QPCR identification of the transdifferentiated target cell line. The cell transdifferentiation method can achieve target cell linetransdifferentiation, so that cells of different sources are transdifferentiated into cellsrelevant to blood vessels, and accordingly the method can be used for cell therapy.

The invention provides an application of Ascl1 in induction of transdifferentiation of astrocytes into functional neurons, and concretely provides a use of an achaete-scute complex homolog-like 1 (Ascl1) gene or a protein or a promoter thereof in preparation of a medicinal composition for inducing astrocytes into functional neurons, and/or in preparation of a medicinal composition for treating nervous system diseases. The application is hopeful to become an effective method for in vitro culture of neurons and generation of new neurons through stimulation in human bodies, so the Ascl1 can be widely applied in treatment of the nervous system diseases, such as neurodegenerative diseases and central nervous trumtic diseases.

The invention discloses a small-molecular compound combination and a method for inducing differentiated cells to prepare vascular smooth muscle cells by using the small-molecular compound combination.The small-molecular compound combination includes a first-stage small-molecular compound and a second-stage small-molecular compound used separately according to time sequence, wherein the first-stage small-molecular compound includes at least one of DNMT inhibitors and lysine deacetylases inhibitors; the second-stage small-molecular compound includes WNT/beta-catenin agonists, cAMP agonists andTG F-beta receptor inhibitors. Through staged induction of the small-molecular compounds, the differentiated cells can be differentiated into the vascular smooth muscle cells, precision quality control can be achieved in each step, and standardization operation and large-scale production are facilitated. The method provided by the invention has wide donor sources, a patient himself can be used asa donor, and the vascular smooth muscle cells needed for basic research, clinical treatment, or tissue engineering production can be obtained in a relatively short period of time.

Methods and compositions are provided for the treatment of a mitochondrial disease in an individual with the mitochondrial disease. Aspects of the methods include administering an inhibitor of a Pumilio-like protein and/or an inhibitor of a serine/arginine-rich family of pre-mRNA splicing factor (SR) protein to a subject. Also provided are methods, compositions, systems and kits for transdifferentiating target cells to neurons, which find use in producing neurons for the development of new therapies, for experimental evaluation, as a source of lineage- and cell- specific products, and the like, for example, for use in treating human disorders of the CNS.

The invention relates to a method for inducing astrocytes to transdifferentiate into 5-hydroxytryptaminergicneuron and application thereof. The invention discloses a method for generating functional 5-hydroxytryptaminergicneuron by using different transcription factor combinations to induce astrocytes to be directly reprogrammed in vitro, and the obtained neurons can survive after being transplanted into the brain. Chemical small molecules are added on the basis of application of transcription factors, so that the efficiency and maturation degree of generating 5-hydroxytryptaminergicneuron canbe further improved. The 5-hydroxytryptaminergicneuron generated by the method can be used for nerve regeneration, simulation of various nervous system diseases and drug screening.

The invention discloses a small-molecular compound combination and a method for inducing differentiated cells to prepare chondrocytes by using the small-molecular compound combination. The method is used for preparing the chondrocytes by directional induction of the differentiated cells. The directed induction includes inhibition of the activity of lysine deacetylase, inhibition of a signal pathway of TGF-beta, inhibition of the activity of PKC, inhibition of the activity of DNA methyltransferase, inhibition of the activity of histone methyltransferase, activation of a WNT/beta-catenin signalpathway, activation of a cAMP signal pathway and activation of an RA signal pathway; the small-molecular compound combination includes compounds for regulating and controlling the signal pathways and/or enzyme activities. Through phased induction of the small-molecular compounds, the differentiated cells can be differentiated into the chondrocytes, precision quality control can be achieved in eachstep, and standardization operation and large-scale production are facilitated. The method provided by the invention has wide donor sources, a patient himself can be used as a donor, and the chondrocytes needed for basic research, clinical treatment, or tissue engineering production can be obtained in a relatively short period of time.

The invention discloses a method for degrading BCL11B protein, which is characterized by comprising the following steps: (1) obtaining Jurkat cell population capable of realizing inducible expression of a KLF4 gene; (2) expressing the KLF4 gene by adding doxycycline to promote the Jurkat cell; (3) obtaining the Jurkat cell protein and RNA of the expressed KLF4 gene; (4) detecting the SUMO conjugation of BCL11B protein obtained in the step (3) in the Jurkat cell of the expressed KLF4 gene through Western Blot detection; (5) carrying out reverse transcription synthesis on the RNA obtained in the step (3) to obtain cDNA, detecting the expression condition of the BCL11B gene by adopting real-time quantitative PCR (polymerase chain reaction) and determining that the specific protein of the BCL11B gene is degraded. The method disclosed by the invention has the advantages that a new degradation way of specific BCL11B protein is found to partially explain the apoptosis reasons of T-ALL cells to provide theoretical guidance for leukemia treatment on one hand and provide a new train of thought for realizing human T cell transdifferentiation on the other hand.

The invention provides a method for inducing transdifferentiation of glial cells into functional neurons and application of the method. Specifically, the invention provides an application of a Neurog2 functional fragment, and the functional fragment can induce glial cells to form functional neuronal cells in vivo or in vitro, not only can play a transdifferentiation role in normal tissues, but also can promote nerve reconstruction of damaged nervous tissues, and is expected to become a new method for in-vivo nervous tissue repair.

The invention discloses a small-molecular compound combination and a method for inducing differentiated cells to prepare osteoblasts by using the small-molecular compound combination. The small-molecular compound combination includes a first-stage small-molecular compound and a second-stage small-molecular compound used in a staged manner according to time sequence, wherein the first-stage small-molecular compound includes TGF-beta receptor inhibitors, WNT/beta-catenin agonists and cAMP agonists; the second-stage small-molecular compound includes lysine deacetylases inhibitors, TGF-beta receptor inhibitors, PKC inhibitors, WNT/beta-catenin agonists and cAMP agonists. Through phased induction of the small-molecular compounds, the differentiated cells can be differentiated into the osteoblasts, precision quality control can be achieved in each step, and standardization operation and large-scale production are facilitated. The method provided by the invention has wide donor sources, a patient himself can be used as a donor, and the osteoblasts needed for basic research, clinical treatment, or tissue engineering production can be obtained in a relatively short period of time.

The invention discloses a method for integrating multi-omics data to presume key protein kinases in cell transdifferentiation. The method comprises the steps of: preparing a cell sample during whole cell transdifferentiation, dividing the cell sample into a transcriptome group and a protein phosphorylation group, and conducting omics tests separately to obtain corresponding original data of each group; pre-processing the original data, screening the protein kinases expressing significant differences through a transcriptome, and screening the protein kinases with activity significant differences and regulation significant differences through a phosphoproteome; and integrating all protein kinases with significant differences, and conducting comprehensive measure to obtain key protein kinases. The method of the invention can provide small-scale candidate kinases for the research of cell transdifferentiation mechanism, provide a guiding direction for the research of the cell transdifferentiation mechanism, greatly narrow the screening range, improve the research efficiency and the accuracy of the experiment, shorten the research and development cycle, increase the success rate of experiments, and reduce the cost of research on cell transdifferentiation mechanisms.

The invention belongs to the technical field of cell transdifferentiation, and discloses a method for inducing differentiation from neuroblastoma cells to neurons. The method comprises the following steps of acquiring the neuroblastoma cells, performing incubation and dispersion treatment to obtain single cell suspension liquid, performing centrifugation for removing supernate, precipitating the cells, adding a culture solution, performing uniform mixing, and performing subculture; and performing differentiation in a differentiation culture medium to form neuroblastoma cell-neurospheres, performing crushing, performing inoculation into a culture container containing an induction culture medium, and performing differentiation culture for 3-7 days to obtain neuronal cells. According to the method for inducing differentiation from the neuroblastoma cells to the neurons, differentiation induced formation of the neurons can be accelerated, so that the proportion of the neuronal cells generated by differentiation of the neuroblastoma cells is greatly increased. Experiments show that on the third day of induction, the neuron proportion is higher than 80%, on the seventh day, the neuron proportion reaches 95%, and the cell maturity and the neurosynaptic growth of the neuronal cells are also improved.

The invention provides a promoter Muller-P which is specifically expressed in a retinal Muller cell, and the sequence of the promoter Muller-P is as shown in SEQ ID NO. 1. The promoter disclosed by the invention has very strong activity of specific expression in a retinal Muller cell, and the recombinant adeno-associated virus based on the promoter has potential clinical application value in gene therapy of retinal diseases related to the Muller cell. Besides, the promoter provided by the invention can specifically express a green fluorescent protein GFP gene in the Muller cell, can realize positioning of the Muller cell and fluorescence labeling of the Muller cell, can be used for screening the Muller cell, and has potential application value in researches such as Muller cell transdifferentiation.

Functional fragments for reprogramming, combinations, and uses thereof. The invention provides a group of transcription factors and a transcription factor combination capable of synergistically promoting the transdifferentiation of glial cells and reprogramming into functional neurons or neuron-like cells, and the glial cells are reprogrammed into functional neurons or neuron-like cells by promoting the expression of the group of transcription factors in vivo or in vitro. The transcription factor can be effectively applied to repairing damage of a nervous system by transdifferentiation of glial cells or limiting deterioration of brain tumors derived from glial cells by utilizing the transdifferentiation capability of key transcription factors, and the application of the found transcription factor and the combination thereof in preparation of medicines for treating nervous system diseases.